+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Global Biopharmaceuticals Market Report and Forecast 2023-2031

  • PDF Icon

    Report

  • 140 Pages
  • May 2023
  • Region: Global
  • Expert Market Research
  • ID: 5805734
The global biopharmaceuticals market value was USD 407.8 billion in 2022, driven by the increasing prevalence of chronic diseases, advancements in biotechnology across the globe. The market size is anticipated to grow at a CAGR of 7.6% during the forecast period of 2023-2031 to achieve a value of USD 788.4 billion by 2031.

Introduction

Biopharmaceuticals, also known as biologics, are a class of pharmaceutical drugs derived from living organisms or produced through biotechnology processes. They are widely used in the treatment and prevention of various diseases, including cancer, autoimmune disorders, and genetic disorders. Biopharmaceuticals offer targeted therapies with high efficacy and fewer side effects compared to traditional chemical-based drugs.

Key Trends in the Biopharmaceuticals Market

Some key trends involved in the Biopharmaceuticals market are as follows:
  • The market for biopharmaceuticals has been experiencing significant growth in recent years. This can be attributed to several key trends shaping the industry:
  • Advancements in Biotechnology: Rapid advancements in biotechnology have revolutionized the development and manufacturing processes of biopharmaceuticals. This includes the use of recombinant DNA technology, genetic engineering, and cell culture techniques to produce complex proteins, antibodies, and other biologically active molecules
  • Increasing Focus on Personalized Medicine: Biopharmaceuticals play a crucial role in personalized medicine, where treatments are tailored to the individual patient based on their genetic profile, biomarkers, and disease characteristics. This trend is driven by advancements in genomic sequencing, biomarker identification, and companion diagnostics, allowing for more targeted and effective therapies

Biopharmaceuticals Market Segmentations

Market Breakup by Product Type

Monoclonal Antibodies

  • Anti-Cancer Monoclonal Antibodies
  • Anti-Inflammatory Monoclonal Antibodies
  • Others

Recombinant Growth Factors

  • Erythropoietin
  • Granulocyte Colony Stimulating Factor

Purified Proteins

  • Leukemia Inhibitory Factor (LIF)
  • P53 Protein
  • P38 Protein
  • Others

Recombinant Proteins

  • Serum Albumin
  • Amyloid Protein
  • Defensin
  • Transferrin

Recombinant Hormones

  • Recombinant Human Growth Hormones
  • Recombinant Insulin
  • Others

Vaccines

  • Recombinant Vaccines
  • Cancer Vaccines
  • Malaria Vaccines
  • Ebola Vaccine
  • Hepatitis B Vaccine
  • Tetanus Vaccine
  • Diphtheria Vaccine
  • Cholera Vaccines
  • Others
  • Conventional Vaccines
  • Polio Vaccine
  • Pox Vaccine
  • Others

Recombinant Enzyme

  • Enterokinase
  • Cyclase
  • Caspase
  • Cathepsin

Cell and Gene Therapies

  • Allogenic Products
  • Autologous Products
  • Acellular Products

Synthetic Immunomodulators

  • Cytokines, Interferons, and Interleukins

Others

Market Breakup by Therapeutic Application

  • Oncology
  • Inflammatory and Infectious Diseases
  • Autoimmune Disorders
  • Metabolic Disorders
  • Hormonal Disorders
  • Cardiovascular Diseases
  • Neurological Diseases
  • Others

Market Breakup by Region

North America

  • United States of America
  • Canada

Europe

  • United Kingdom
  • Germany
  • France
  • Italy
  • Others

Asia Pacific

  • China
  • Japan
  • India
  • ASEAN
  • Australia
  • Others

Latin America

  • Brazil
  • Argentina
  • Mexico
  • Others

Middle East and Africa

  • Saudi Arabia
  • United Arab Emirates
  • Nigeria
  • South Africa
  • Others

Biopharmaceuticals Market Scenario

The biopharmaceuticals market is a rapidly growing and dynamic sector within the pharmaceutical industry. Biopharmaceuticals, also known as biologics, are a class of drugs that are derived from living organisms or produced through biotechnology processes. They have revolutionized the treatment and prevention of various diseases, offering targeted therapies with high efficacy and fewer side effects compared to traditional chemical-based drugs.

The market for biopharmaceuticals has experienced significant growth in recent years, driven by factors such as increasing prevalence of chronic diseases, advancements in biotechnology, and growing demand for personalized medicine. Biopharmaceuticals have demonstrated remarkable success in treating conditions such as cancer, autoimmune disorders, diabetes, and rare genetic diseases.

Overall, the biopharmaceuticals market presents significant opportunities for growth and innovation. With ongoing research and development efforts, increasing investment in biotechnology, and evolving regulatory frameworks, the market is expected to continue its upward trajectory in the coming years. The focus on personalized medicine, biosimilars, and expanding access to biopharmaceuticals globally will be key drivers of market growth.

Biopharmaceuticals Market: Competitor Landscape

The key features of the market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:
  • Amgen Inc
  • AbbVie Inc
  • Bristol-Myers Squibb Company
  • Eli Lilly and Company
  • Novo Nordisk A/S
  • Pfizer Inc
  • GlaxoSmithKline plc
  • Abbott
  • Astrazeneca
  • F. Hoffmann-La Roche Ltd
  • Merck & Co., Inc
  • Bayer AG
  • Biogen

Table of Contents

1 Preface
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage - Key Segmentation and Scope
1.4 Research Methodology
2 Executive Summary
3 Global Biopharmaceuticals Market Overview
3.1 Global Biopharmaceuticals Market Historical Value (2016-2022)
3.2 Global Biopharmaceuticals Market Forecast Value (2023-2031)
4 Global Biopharmaceuticals Market Landscape
4.1 Global Biopharmaceuticals Developers Landscape
4.1.1 Analysis by Year of Establishment
4.1.2 Analysis by Company Size
4.1.3 Analysis by Region
4.2 Global Biopharmaceuticals Product Landscape
4.2.1 Analysis by Product Type
4.2.2 Analysis by Therapeutic Application
5 Global Biopharmaceuticals Market Dynamics
5.1 Market Drivers and Constraints
5.2 SWOT Analysis
5.3 Porter’s Five Forces Model
5.4 Key Demand Indicators
5.5 Key Price Indicators
5.6 Industry Events, Initiatives, and Trends
5.7 Value Chain Analysis
6 Global Biopharmaceuticals Market Segmentation
6.1 Global Biopharmaceuticals Market by Product Type
6.1.1 Market Overview
6.1.2 Monoclonal Antibodies
6.1.2.1 Anti-Cancer Monoclonal Antibodies
6.1.2.2 Anti-Inflammatory Monoclonal Antibodies
6.1.2.3 Others
6.1.3 Recombinant Growth Factors
6.1.3.1 Erythropoietin
6.1.3.2 Granulocyte Colony Stimulating Factor
6.1.4 Purified Proteins
6.1.4.1 Leukemia Inhibitory Factor (LIF)
6.1.4.2 P53 Protein
6.1.4.3 P38 Protein
6.1.4.4 Others
6.1.5 Recombinant Proteins
6.1.5.1 Serum Albumin
6.1.5.2 Amyloid Protein
6.1.5.3 Defensin
6.1.5.4 Transferrin
6.1.6 Recombinant Hormones
6.1.6.1 Recombinant Human Growth Hormones
6.1.6.2 Recombinant Insulin
6.1.6.3 Others
6.1.7 Vaccines
6.1.7.1 Recombinant Vaccines
6.1.7.1.1 Cancer Vaccines
6.1.7.1.2 Malaria Vaccines
6.1.7.1.3 Ebola Vaccine
6.1.7.1.4 Hepatitis B Vaccine
6.1.7.1.5 Tetanus Vaccine
6.1.7.1.6 Diphtheria Vaccine
6.1.7.1.7 Cholera Vaccines
6.1.7.1.8 Others
6.1.7.2 Conventional Vaccines
6.1.7.2.1 Polio Vaccine
6.1.7.2.2 Pox Vaccine
6.1.7.2.3 Others
6.1.8 Recombinant Enzyme
6.1.8.1 Enterokinase
6.1.8.2 Cyclase
6.1.8.3 Caspase
6.1.8.4 Cathepsin
6.1.9 Cell and Gene Therapies
6.1.9.1 Allogenic Products
6.1.9.2 Autologous Products
6.1.9.3 Acellular Products
6.1.10 Synthetic Immunomodulators
6.1.10.1 Cytokines, Interferons, and Interleukins
6.1.11 Others
6.2 Global Biopharmaceuticals Market by Therapeutic Application
6.2.1 Market Overview
6.2.2 Oncology
6.2.3 Inflammatory and Infectious Diseases
6.2.4 Autoimmune Disorders
6.2.5 Metabolic Disorders
6.2.6 Hormonal Disorders
6.2.7 Cardiovascular Diseases
6.2.8 Neurological Diseases
6.2.9 Others
6.3 Global Biopharmaceuticals Market by Region
6.3.1 Market Overview
6.3.2 North America
6.3.3 Europe
6.3.4 Asia Pacific
6.3.5 Latin America
6.3.6 Middle East and Africa
7 North America Biopharmaceuticals Market
7.1 Market Share by Country
7.2 United States of America
7.3 Canada
8 Europe Biopharmaceuticals Market
8.1 Market Share by Country
8.2 United Kingdom
8.3 Germany
8.4 France
8.5 Italy
8.6 Others
9 Asia Pacific Biopharmaceuticals Market
9.1 Market Share by Country
9.2 China
9.3 Japan
9.4 India
9.5 ASEAN
9.6 Australia
9.7 Others
10 Latin America Biopharmaceuticals Market
10.1 Market Share by Country
10.2 Brazil
10.3 Argentina
10.4 Mexico
10.5 Others
11 Middle East and Africa Biopharmaceuticals Market
11.1 Market Share by Country
11.2 Saudi Arabia
11.3 United Arab Emirates
11.4 Nigeria
11.5 South Africa
11.6 Others
12 Patent Analysis
12.1 Analysis by Type of Patent
12.2 Analysis by Publication year
12.3 Analysis by Issuing Authority
12.4 Analysis by Patent Age
12.5 Analysis by CPC Analysis
12.6 Analysis by Patent Valuation
12.7 Analysis by Key Players
13 Grants Analysis
13.1 Analysis by year
13.2 Analysis by Amount Awarded
13.3 Analysis by Issuing Authority
13.4 Analysis by Grant Application
13.5 Analysis by Funding Institute
13.6 Analysis by NIH Departments
13.7 Analysis by Recipient Organization
14 Funding Analysis
14.1 Analysis by Funding Instances
14.2 Analysis by Type of Funding
14.3 Analysis by Funding Amount
14.4 Analysis by Leading Players
14.5 Analysis by Leading Investors
14.6 Analysis by Geography
15 Partnership and Collaborations Analysis
15.1 Analysis by Partnership Instances
15.2 Analysis by Type of Partnership
15.3 Analysis by Leading Players
15.4 Analysis by Geography
16 Regulatory Framework
16.1 Regulatory Overview
16.1.1 US FDA
16.1.2 EU EMA
16.1.3 INDIA CDSCO
16.1.4 JAPAN PMDA
16.1.5 Others
17 Supplier Landscape
17.1 Amgen Inc.
17.1.1 Financial Analysis
17.1.2 Product Portfolio
17.1.3 Demographic Reach and Achievements
17.1.4 Mergers and Acquisitions
17.1.5 Certifications
17.2 AbbVie Inc.
17.2.1 Financial Analysis
17.2.2 Product Portfolio
17.2.3 Demographic Reach and Achievements
17.2.4 Mergers and Acquisitions
17.2.5 Certifications
17.3 Bristol-Myers Squibb Company.
17.3.1 Financial Analysis
17.3.2 Product Portfolio
17.3.3 Demographic Reach and Achievements
17.3.4 Mergers and Acquisitions
17.3.5 Certifications
17.4 Eli Lilly and Company
17.4.1 Financial Analysis
17.4.2 Financial Portfolio
17.4.3 Demographic Reach and Achievements
17.4.4 Mergers and Acquisitions
17.4.5 Certifications
17.5 Novo Nordisk A/S
17.5.1 Financial Analysis
17.5.2 Product Portfolio
17.5.3 Demographic Reach and Achievements
17.5.4 Mergers and Acquisitions
17.5.5 Certifications
17.6 Pfizer Inc.
17.6.1 Financial Analysis
17.6.2 Product Portfolio
17.6.3 Demographic Reach and Achievements
17.6.4 Mergers and Acquisitions
17.6.5 Certifications
17.7 GlaxoSmithKline plc.
17.7.1 Financial Analysis
17.7.2 Product Portfolio
17.7.3 Demographic Reach and Achievements
17.7.4 Mergers and Acquisitions
17.7.5 Certifications
17.8 Abbott
17.8.1 Financial Analysis
17.8.2 Product Portfolio
17.8.3 Demographic Reach and Achievements
17.8.4 Mergers and Acquisitions
17.8.5 Certifications
17.9 Astrazeneca
17.9.1 Financial Analysis
17.9.2 Product Portfolio
17.9.3 Demographic Reach and Achievements
17.9.4 Mergers and Acquisitions
17.9.5 Certifications
17.10 F. Hoffmann-La Roche Ltd.
17.10.1 Financial Analysis
17.10.2 Product Portfolio
17.10.3 Demographic Reach and Achievements
17.10.4 Mergers and Acquisitions
17.10.5 Certifications
17.11 Merck & Co., Inc.
17.11.1 Financial Analysis
17.11.2 Product Portfolio
17.11.3 Demographic Reach and Achievements
17.11.4 Mergers and Acquisitions
17.11.5 Certifications
17.12 Bayer AG
17.12.1 Financial Analysis
17.12.2 Product Portfolio
17.12.3 Demographic Reach and Achievements
17.12.4 Mergers and Acquisitions
17.12.5 Certifications
17.13 Biogen
17.13.1 Financial Analysis
17.13.2 Product Portfolio
17.13.3 Demographic Reach and Achievements
17.13.4 Mergers and Acquisitions
17.13.5 Certifications
18 Global Biopharmaceuticals Market - Distribution Model (Additional Insight)
18.1 Overview
18.2 Potential Distributors
18.3 Key Parameters for Distribution Partner Assessment
19 Key Opinion Leaders (KOL) Insights (Additional Insight)
20 Company Competitiveness Analysis (Additional Insight)
20.1 Very Small Companies
20.2 Small Companies
20.3 Mid-Sized Companies
20.4 Large Companies
20.5 Very Large Companies
21 Payment Methods (Additional Insight)
21.1 Government Funded
21.2 Private Insurance
21.3 Out-of-Pocket

Companies Mentioned

  • Amgen Inc.
  • AbbVie Inc.
  • Bristol-Myers Squibb Company.
  • Eli Lilly and Company
  • Novo Nordisk A/S
  • Pfizer Inc.
  • GlaxoSmithKline plc.
  • Abbott
  • Astrazeneca
  • F. Hoffmann-La Roche Ltd.
  • Merck & Co. Inc.
  • Bayer AG
  • Biogen

Methodology

Loading
LOADING...

Table Information